Rohto PharmaceuticalLtd Management
Management criteria checks 4/4
Rohto PharmaceuticalLtd's CEO is Yamada Kunio, appointed in Jun 2009, has a tenure of 14.92 years. total yearly compensation is ¥205.00M, comprised of 89.3% salary and 10.7% bonuses, including company stock and options. directly owns 1.74% of the company’s shares, worth MX$1.19B. The average tenure of the management team and the board of directors is 2.2 years and 4.9 years respectively.
Key information
Yamada Kunio
Chief executive officer
JP¥205.0m
Total compensation
| CEO salary percentage | 89.3% |
| CEO tenure | 14.9yrs |
| CEO ownership | 1.7% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | JP¥31b |
| Dec 31 2023 | n/a | n/a | JP¥31b |
| Sep 30 2023 | n/a | n/a | JP¥30b |
| Jun 30 2023 | n/a | n/a | JP¥28b |
| Mar 31 2023 | JP¥205m | JP¥183m | JP¥26b |
| Dec 31 2022 | n/a | n/a | JP¥26b |
| Sep 30 2022 | n/a | n/a | JP¥23b |
| Jun 30 2022 | n/a | n/a | JP¥23b |
| Mar 31 2022 | JP¥196m | JP¥178m | JP¥21b |
| Dec 31 2021 | n/a | n/a | JP¥23b |
| Sep 30 2021 | n/a | n/a | JP¥21b |
| Jun 30 2021 | n/a | n/a | JP¥20b |
| Mar 31 2021 | JP¥185m | JP¥176m | JP¥17b |
| Dec 31 2020 | n/a | n/a | JP¥14b |
| Sep 30 2020 | n/a | n/a | JP¥14b |
| Jun 30 2020 | n/a | n/a | JP¥15b |
| Mar 31 2020 | JP¥192m | JP¥179m | JP¥15b |
| Dec 31 2019 | n/a | n/a | JP¥11b |
| Sep 30 2019 | n/a | n/a | JP¥10b |
| Jun 30 2019 | n/a | n/a | JP¥9b |
| Mar 31 2019 | JP¥181m | JP¥173m | JP¥10b |
Compensation vs Market: Yamada's total compensation ($USD1.31M) is about average for companies of similar size in the MX market ($USD1.49M).
Compensation vs Earnings: Yamada's compensation has been consistent with company performance over the past year.
CEO
Yamada Kunio (67 yo)
14.9yrs
Tenure
JP¥205,000,000
Compensation
Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 14.9yrs | JP¥205.00m | 1.74% ¥ 1.2b | |
| President & Representative Director | 4.9yrs | no data | 0.0066% ¥ 4.5m | |
| VP, CFO & Director | 2.2yrs | no data | 0.020% ¥ 13.7m | |
| EVP, CTO & Director | 2.2yrs | no data | 0.017% ¥ 11.6m | |
| Chief Communication Officer & Director | less than a year | no data | no data | |
| Senior Executive Officer and General Manager of Marketing Division | no data | no data | 0.0048% ¥ 3.3m | |
| CHRO & Director | less than a year | no data | no data | |
| MD, Chief Strategy Officer & Director | 2.2yrs | no data | 0.0035% ¥ 2.4m |
2.2yrs
Average Tenure
62yo
Average Age
Experienced Management: 4527 N's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 24.9yrs | JP¥205.00m | 1.74% ¥ 1.2b | |
| President & Representative Director | 4.9yrs | no data | 0.0066% ¥ 4.5m | |
| VP, CFO & Director | 12.9yrs | no data | 0.020% ¥ 13.7m | |
| EVP, CTO & Director | 13.9yrs | no data | 0.017% ¥ 11.6m | |
| Chief Communication Officer & Director | less than a year | no data | no data | |
| CHRO & Director | less than a year | no data | no data | |
| MD, Chief Strategy Officer & Director | 5.9yrs | no data | 0.0035% ¥ 2.4m | |
| Standing Corporate Auditor | 7.9yrs | no data | 0.027% ¥ 18.2m | |
| Independent Outside Director | 4.9yrs | no data | no data | |
| Independent Outside Director | 3.9yrs | no data | no data | |
| Independent Outside Director | 1.9yrs | no data | no data | |
| Independent Outside director | 1.9yrs | no data | no data |
4.9yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 4527 N's board of directors are considered experienced (4.9 years average tenure).